Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Denosumab vs zoledronic acid for bone loss in early breast cancer on aromatase inhibitors
ChiCTR2200066151Phase 4Not yet recruiting
- Sponsor
- First Hospital of China Medical University
- Start
- Nov 2022
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of denosumab and zoledronic acid in osteoporosis, osteopenia and breast cancer (2 arms), sponsored by First Hospital of China Medical University. Primary endpoint: Change in bone mineral density at lumbar spine at 24 months. Planned start Nov 2022; status: not yet recruiting.
02
Drugs
denosumabzoledronic acid
03
Conditions
osteoporosisosteopeniabreast cancer
Beyond the preview
Go deeper on ChiCTR2200066151.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200066151.